One year in review
Gout: one year in review 2023
L. Punzi1, P. Galozzi2, R. Luisetto3, A. Scanu4, R. Ramonda5, F. Oliviero6
- Centre for Gout and Metabolic Bone and Joint Diseases, Ospedale Civile SS. Giovanni e Paolo, Venezia, Italy. punzileonardo@gmail.com
- Laboratory Medicine Unit, Department of Medicine-DIMED, University of Padova, Italy.
- Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padova, Italy.
- Department of Woman's and Child's Health, University of Padova, Italy.
- Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy.
- Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy.
CER17308
2024 Vol.42, N°1
PI 0001, PF 0009
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 38306017 [PubMed]
Received: 17/11/2023
Accepted : 08/01/2024
In Press: 24/01/2024
Published: 24/01/2024
Abstract
Gout is a chronic joint disease caused by the deposition of monosodium urate crystals into and around the articular tissues. In the last two years, new insights regarding diagnosis, genetic involvement, pathogenesis, comorbidities, and clinical data, have allowed the identification of new strategies to improve the control of the disease and its flares. In keeping, the discover of new mechanisms concerning crystal-induced inflammation have suggested new ways for the management not only of gout, but also other systemic diseases, mainly including renal and cardiovascular disorders. In this context it is very representative the case of colchicine which, given the surprising results obtained both in laboratory and clinical experiments, has recently received by FDA the approval for the prevention of cardiovascular disorders.
